Her2/neu negative Trials in Washington D.c, United States
Conditions / Her2/neu negative / Washington D.c, United States
Her2/neu negative has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | COMPLETED | PHASE3 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | ACTIVE_NOT_RECRUITING | — |
| NCT00785291 | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | COMPLETED | PHASE3 |
| NCT02860000 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | COMPLETED | PHASE2 |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | TERMINATED | PHASE1/PHASE2 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | ACTIVE_NOT_RECRUITING | — |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | ACTIVE_NOT_RECRUITING | — |
| NCT03633331 | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | COMPLETED | — |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |